Broader equities have not performed particularly well in 2025. The S&P 500 is barely in the black year to date.
|
In the most recent trading session, Merck (MRK) closed at $80.32, indicating a -1.27% shift from the previous trading day.
|
An analysts downbeat new take on Summit Therapeutics (NASDAQ: SMMT) pushed its stock downward on Hump Day. At the end
|
Many blue chip stocks pay attractive dividends. The Dow Jones Industrial Average (DJINDICES: ^DJI) is loaded with blue chip stocks.
|
Merck (MRK) closed at $81.35 in the latest trading session, marking a +2.55% move from the prior day.
|
|
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how
|
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
|
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
|